このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer (PluvEquity)

2026年9月30日 更新者:Jacob Berchuck, MD、Emory University

A Phase II Study to Validate the Efficacy and Safety of Pluvicto in African American Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This phase II trial tests how well Pluvicto works in treating African American patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has continued to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production (castration-resistant). Pluvicto is a targeted radioligand therapy. It works like a guided missile, combining tumor seeking molecules with a radioactive isotope. It circulates through the bloodstream, binds to a protein on prostate cancer cells called prostate specific membrane antigen, and destroys them using radiation. Pluvicto is approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. This trial may help researchers determine the safety and efficacy of Pluvicto specifically in African American patients with metastatic castration-resistant prostate cancer.

調査の概要

詳細な説明

PRIMARY OBJECTIVE:

I. To establish the clinical efficacy of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in African American (AA) men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on one androgen receptor pathway inhibitor (ARPI) and have not been treated with taxane chemotherapy for mCRPC.

SECONDARY OBJECTIVES:

I. To establish in AA men with mCRPC who have progressed on one androgen receptor (AR) pathway inhibitor and have not been treated with taxane chemotherapy for mCRPC the:

Ia. Safety and tolerability of Pluvicto; Ib. Overall survival following treatment with Pluvicto; Ic. Objective radiographic response rate to Pluvicto; Id. Prostate specific antigen (PSA) response rate to Pluvicto; Ie. Impact of Pluvicto on quality of life.

TERTIARY/EXPLORATORY OBJECTIVES:

I. Identify tumor genomic and transcriptional profiles that are associated with response to Pluvicto in AA men.

II. Identify circulating tumor deoxyribonucleic acid (DNA) molecular features that are associated with response to Pluvicto in AA men.

III. Evaluate the association of genetic ancestry with response to Pluvicto in AA men.

OUTLINE:

Patients receive Pluvicto intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo prostate specific membrane antigen (PSMA) positron emission tomography (PET), computed tomography (CT), bone scan, single photon emission computed tomography (SPECT), collection of blood samples, and optional biopsy throughout the trial.

After completion of study treatment, patients are followed up every 3 months for up to 36 months.

研究の種類

介入

入学 (推定)

88

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Emory University Hospital/Winship Cancer Institute
        • コンタクト:
        • 主任研究者:
          • Jacob E. Berchuck, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

Inclusion Criteria:

  • Participants must have the ability to understand and sign an approved informed consent form (ICF) prior to participation in any study procedures

  • Participants must have the ability to understand and comply with all protocol requirements

  • Participants must have the ability to understand and comply with institutional radiation safety requirements

  • Participants must be ≥ 18 years of age

  • Participants must self-identify as being African-American

  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

  • Participants must have histological pathological, and/or cytological confirmation of adenocarcinoma of the prostate

  • Participants have PSMA-positive disease on PSMA scan

  • Participants must have a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L)

  • Participants must have progressed only once on prior second generation androgen receptor-directed therapy (ARDT) (abiraterone, enzalutamide, darolutamide, or apalutamide)

    • First generation androgen receptor inhibitor therapy (e.g. bicalutamide) is allowed but not considered as prior ARDT therapy
    • Second generation ARDT must be the most recent therapy received
  • Participants must have progressive mCRPC. Documented progressive mCRPC will be based on at least 1 of the following criteria:

    • Serum/plasma PSA progression defined as 2 increases in PSA measured at least 1 week apart. The minimal start value is 2.0 ng/mL; 1.0 ng/mL is the minimal starting value if confirmed rise in PSA is the only indication of progression
    • Soft-tissue progression defined (Prostate Cancer Working Group Scher Prostate Cancer 2016 Oncology Response Criteria [PCWG3]-modified Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1 [Eisenhauer et al 2009, Scher et al 2016])
    • Progression of bone disease: two new lesions; only positivity on the bone scan defines metastatic disease to bone (PCWG3 criteria [Scher et al 2016])
  • Participants must have ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization

  • Participants must have recovered to ≤ grade 2 from all clinically significant toxicities related to prior therapies (i.e. prior chemotherapy, radiation, etc.) except alopecia

  • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

  • Platelets ≥ 100 x 10^9/L

  • Hemoglobin ≥ 9 g/dL

  • Total bilirubin < 2 x the institutional upper limit of normal (ULN). For participants with known Gilbert's syndrome ≤ 3 x ULN is permitted

  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0 x ULN OR ≤ 5.0 x ULN for participants with liver metastases

  • Estimate glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73m^2 using the Modification of Diet in Renal Disease (MDRD) equation

  • Albumin ≥ 2.5 g/dL

  • Candidates for change in ARDT as assessed by the treating physician

    • Participants cannot have previously progressed nor had intolerable toxicity to both enzalutamide and abiraterone

Exclusion Criteria:

  • Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation

  • Previous PSMA-targeted radioligand therapy is not allowed

  • Prior treatment with cytotoxic chemotherapy for castration resistant or castrate sensitive prostate cancer (e.g., taxanes, platinum, estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy (including monoclonal antibodies). (Note: Taxane exposure [maximum 6 cycles] in the adjuvant or neoadjuvant setting is allowed if 12 months have elapsed since completion of this adjuvant or neoadjuvant therapy. Prior treatment with sipuleucel-T is allowed)

  • Any investigational agents within 28 days prior to day of randomization

  • Known hypersensitivity to any of the study treatments or its excipients or to drugs of similar classes

  • Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, biological therapy, or investigational therapy

  • Transfusion or use of bone marrow stimulating agents for the sole purpose of making a subject eligible for study inclusion

  • Participants with a history of central nervous system (CNS) metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. Participants with CNS metastases are eligible if received therapy (surgery, radiotherapy, gamma knife), asymptomatic and neurologically stable without corticosteroids. Participants with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired

  • A superscan as seen in the baseline bone scan, defined as 99mTc bone scintigraphy pattern demonstrating diffuse, confluent, and intense radiotracer uptake throughout the majority of the axial and appendicular skeleton, with markedly reduced or absent renal visualization and minimal soft tissue activity

  • Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression

  • History or current diagnosis of the following electrocardiography (ECG) abnormalities indicating significant risk of safety for study participants:

    • Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block)
    • History of familial long QT syndrome or known family history of Torsades de Pointe
    • Cardiac or cardiac repolarization abnormality, including any of the following: history of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to starting study treatment
  • Concurrent serious (as determined by the principal investigator) medical conditions, including, but not limited to New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation

    • HIV-infected participants who are at a low risk of AIDS-related outcomes may participate in this trial
    • Participants with an active documented coronavirus disease 2019 (COVID-19) infection (any grade of disease severity) at time of informed consent may be included only when completely recovered (in accordance with local guidance)
  • Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. Participants with a prior history of malignancy that has been adequately treated and who have been disease free and treatment free for more than 3 years prior to randomization are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer

  • Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF

  • Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: Participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (including [incl.] pads, drainage) are allowed

  • History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study

  • Any condition that precludes raised arms position

  • Eligible for treatments other than ARDT based on presence of any mutations or biomarkers that are known as predictors of better response (e.g., AR-V7 or BRCA)

  • Not able to understand and to comply with study instructions and requirements

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (Pluvicto)

Patients receive Pluvicto IV on day 1 of each cycle. Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET scan, CT scan, bone scan, collection of blood samples, and optional SPECT scans and pre- and post-treatment biopsies.

Undergo CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Ancillary studies

Undergo biopsy

他の名前:
  • Bx
  • BIOPSY_TYPE
  • 生検

Undergo collection of blood samples

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集
  • サンプル収集

Undergo bone scan

他の名前:
  • 骨シンチグラフィー

Given IV

他の名前:
  • 177Lu標識PSMA-617
  • 177Lu-PSMA-617
  • プルビクト
  • Lu177-PSMA-617
  • ルテチウム-177-PSMA-617
  • AAA617
  • AAA-617
  • ルテチウム Lu 177-PSMA-617
  • ルテチウム LU-177 ビピボタイド テトラキセタン

Undergo SPECT

他の名前:
  • ST
  • 医用画像、単一光子放出コンピュータ断層撮影
  • 単一光子放出断層撮影
  • 単一光子放出コンピュータ断層撮影
  • スペクト
  • SPECTイメージング
  • スペクトスキャン
  • SPET
  • トモグラフィー、計算された放出、単一光子
  • トモグラフィー、放射計算、単一光子
  • 計算された単一光子放出

Undergo PSMA PET scan

他の名前:
  • PSMAペット
  • 前立腺特異的膜抗原 PET
  • PSMA-陽電子放射断層撮影

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Radiographic progression-free survival (rPFS)
時間枠:From the start of study treatment to the first objective documentation of radiographic disease progression or death, assessed up to 36 months

Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median rPFS will be estimated using the Brookmeyer-Crowley approach.

From the start of study treatment to the first objective documentation of radiographic disease progression or death, assessed up to 36 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of adverse events
時間枠:Up to 36 months

Will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Frequencies and percentages will be used to summarize safety events. Toxicities will be tabulated by grade, association, and cycle number.

Up to 36 months
Overall survival
時間枠:From the start of study treatment to the date of death, assessed up to 36 months

Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median overall survival will be estimated using the Brookmeyer-Crowley approach.

From the start of study treatment to the date of death, assessed up to 36 months
Objective response rate
時間枠:Up to 36 months

ORR is defined as the proportion of subjects achieving a best overall response of complete response (CR) or partial response (PR). Will be summarized with a 2-sided 95% confidence interval using the Clopper-Pearson method.

Up to 36 months
Disease control rate (DCR)
時間枠:Up to 36 months

DCR is defined as the proportion of subjects achieving a best overall response of CR, PR, or stable disease.

Up to 36 months
Prostate specific antigen (PSA) response rate
時間枠:Up to 36 months

Will be defined as the proportion of subjects achieving a ≥ 50% decline (PSA50) or ≥ 90% decline (PSA90) in PSA from baseline, confirmed per Prostate Cancer Working Group Scher Prostate Cancer 2016 Oncology Response criteria. PSA50 and PSA90 will be summarized with 2-sided 95% confidence intervals using the Clopper-Pearson method.

Up to 36 months
Health related quality of life (FACT-P)
時間枠:Up to 36 months

Will be quantified through patient-reported outcome instruments administered during study participation using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Descriptive statistics such as mean, median, interquartile range, and min/max will be reported for continuous variables, and frequencies and percentages will be reported for categorical variables.

Up to 36 months
Health related quality of life (FACT-RNT)
時間枠:Up to 36 months

Will be quantified through patient-reported outcome instruments administered during study participation using the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT). Descriptive statistics such as mean, median, interquartile range, and min/max will be reported for continuous variables, and frequencies and percentages will be reported for categorical variables.

Up to 36 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jacob E Berchuck, MD、Emory University Hospital/Winship Cancer Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月2日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年9月25日

QC基準を満たした最初の提出物

2026年9月30日

最初の投稿 (実際)

2026年10月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する